Department of Radiology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, No. 55, 4th Section of South Ren-min Road, Chengdu 610041, China.
Department of Radiology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, No. 55, 4th Section of South Ren-min Road, Chengdu 610041, China.
Acad Radiol. 2020 Mar;27(3):e35-e44. doi: 10.1016/j.acra.2019.05.002.
The aim of the present study was to use pharmacokinetic quantitative parameters with histogram and texture features on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to differentiate between the luminal A and luminal B molecular subtypes of breast cancer.
We retrospectively reviewed the data of 94 patients with histopathologically proven breast cancer. The pharmacokinetic quantitative parameters (K, K, and V) with their corresponding histogram and texture features based on preoperative DCE-MRI were obtained. The parameters were compared using the Mann-Whitney U-test between the luminal A and luminal B groups, the human epidermal growth factor receptor-2 (HER2)-positive luminal B and HER2-negative luminal B groups, and the lymph node metastasis (LNM)-positive and LNM-negative groups. Receiver operating characteristic curves were generated for parameters that presented significant between-group differences.
The maximum values of K, K, and V, and the mean and 90th percentile values of V were significantly higher in the luminal B group than in the luminal A group. Among the texture features, only skewness of K significantly differed between the luminal A and B groups. All histogram features of K were higher in the HER2-positive luminal B group than in the HER2-negative luminal B group. However, no parameter differed between the LNM-positive and LNM-negative groups.
Pharmacokinetic quantitative parameters with histogram and texture features obtained from DCE-MRI are associated with the molecular subtypes of breast cancer, and may serve as potential imaging biomarkers to differentiate between the luminal A and luminal B molecular subtypes.
本研究旨在利用动态对比增强磁共振成像（DCE-MRI）的药代动力学定量参数及其直方图和纹理特征，区分乳腺癌的管腔 A 和管腔 B 分子亚型。
我们回顾性分析了 94 例经组织病理学证实的乳腺癌患者的资料。在术前 DCE-MRI 上获得药代动力学定量参数（K、K 和 V）及其相应的直方图和纹理特征。采用 Mann-Whitney U 检验比较管腔 A 组和管腔 B 组、人表皮生长因子受体 2（HER2）阳性管腔 B 组和 HER2 阴性管腔 B 组以及淋巴结转移（LNM）阳性组和 LNM 阴性组之间的参数。对具有显著组间差异的参数生成受试者工作特征曲线。
管腔 B 组的 K、K 和 V 的最大值以及 V 的均值和 90 分位数明显高于管腔 A 组。在纹理特征中，只有 K 的偏度在管腔 A 和 B 组之间存在显著差异。K 的所有直方图特征在 HER2 阳性管腔 B 组中均高于 HER2 阴性管腔 B 组。然而，LNM 阳性组和 LNM 阴性组之间没有参数差异。
从 DCE-MRI 获得的药代动力学定量参数及其直方图和纹理特征与乳腺癌的分子亚型相关，可能成为区分管腔 A 和管腔 B 分子亚型的潜在影像学生物标志物。
